Working… Menu

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03535870
Recruitment Status : Recruiting
First Posted : May 24, 2018
Last Update Posted : June 1, 2018
Information provided by (Responsible Party):
West-Ward Pharmaceutical

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : March 2019